ICAM1 and non-small cell lung carcinoma: Interestingly, patients with non‐small cell lung cancer (NSCLC) responsive to immune checkpoint inhibitor (ICI) therapy have higher soluble ICAM‐1 (sICAM‐1) levels in their plasma.